{
  "source": "PA-Notification-Brukinsa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1306-6\nProgram Prior Authorization/Notification\nMedication Brukinsa® (zanubrutinib)\nP&T Approval Date 1/2020, 1/2021, 10/2021, 10/2022, 10/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nBrukinsa (zanubrutinib) is a kinase inhibitor indicated for the treatment of patients with mantle\ncell lymphoma (MCL) who have received at least one prior therapy, relapsed or refractory\nmarginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen, and\nrelapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or\nmore lines of systemic therapy. These indications are approved under accelerated approval based\non overall response rate. Continued approval for these indications may be contingent upon\nverification and description of clinical benefit in a confirmatory trial. Brukinsa is also indicated\nfor the treatment of Waldenström’s macroglobulinemia (WM) and chronic lymphocytic leukemia\n(CLL) or small lymphocytic lymphoma (SLL).\nNCCN recommends Brukinsa for relapsed/refractory hairy cell leukemia and as second-line and\nsubsequent therapy for extranodal marginal zone lymphoma (EMZL) of the stomach, extranodal\nmarginal zone lymphoma of nongastric sites (noncutaneous), nodal marginal zone, and splenic\nmarginal zone lymphomas.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Brukinsa will be approved based on the following criterion:\na. Patient is less than 19 ye",
    "efit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Brukinsa will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. B-Cell Lymphomas\n1. Initial Authorization\na. Brukinsa will be approved based on one of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) All of the following:\n(a) Diagnosis of follicular lymphoma (FL)\n-AND-\n(b) Disease is relapsed or refractory\n-AND-\n(c) Patient has received at least two or more lines of systemic therapy\n-AND-\n(d) Brukinsa will be used in combination with obinutuzumab\n-OR-\n(2) All of the following:\n(a) Diagnosis of one of the following:\ni. Extranodal marginal zone lymphoma (EMZL) of the stomach\nii. Extranodal marginal zone lymphoma of nongastric sites (noncutaneous)\niii. Nodal marginal zone lymphoma\n-AND-\n(b) Disease is relapsed, refractory, or progressive\n-AND-\n(c) Patient has received at least one anti-CD20-based regimen (e.g., rituximab,\nobinutuzumab)\n-OR-\n(3) All of the following:\n(a) Diagnosis of splenic marginal zone lymphoma\n-AND-\n(b) Disease is relapsed or refractory\n-AND-\n(c) Patient has received at least one anti-CD20-based regimen (e.g., rituximab,\nobinutuzumab)\n© 2024 UnitedHealthcare Services, Inc.\n2\n-OR-\n(4) Diagnosis of mantle cell lymphoma (MCL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Brukinsa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Brukinsa\ntherapy\nAuthorization will be issued for 12 months.\nC. Waldenström’s Macroglobulinemia (WM)\n1. Initial Authorization\na. Brukinsa will be approved based on the following criterion:\n(1) Diagnosis of Waldenström’s macroglobulinemia (WM)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Brukinsa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on",
    "ia (WM)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Brukinsa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Brukinsa\ntherapy\nAuthorization will be issued for 12 months.\nD. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)\n1. Initial Authorization\na. Brukinsa will be approved based on the following criterion:\n(1) Diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\n(CLL/SLL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Brukinsa will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Patient does not show evidence of progressive disease while on Brukinsa\ntherapy\nAuthorization will be issued for 12 months.\nE. Hairy Cell Leukemia\n1. Initial Authorization\na. Brukinsa will be approved based on the following criteria:\n(1) Diagnosis of hairy cell leukemia\n-AND-\n(2) Disease is relapsed, refractory, or progressive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Brukinsa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Brukinsa\ntherapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-a",
    "e Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n4\n4. References:\n1. Brukinsa® [package insert]. BeiGene, Ltd., San Mateo, CA, March 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed May 31,\n2024.\nProgram Prior Authorization/Notification – Brukinsa® (zanubrutinib)\nChange Control\n1/2020 New program.\n1/2021 Annual review. Background updated to reflect package insert. No\nchanges to coverage criteria. References updated.\n10/2021 Clinical coverage criteria added for Waldenström’s Macroglobulinemia,\nMarginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small\nLymphocytic. Clinical coverage criteria updated for other B-Cell\nLymphomas. Updated background and references.\n10/2022 Annual review. Updates made to B-Cell Lymphoma and CLL/SLL\ncriteria based on NCCN recommendations. Updated background and\nreference. Added state mandate footnote.\n10/2023 Annual review. Updates made to B-Cell Lymphoma criteria based on\nNCCN recommendations. Updated background and reference.\n7/2024 Annual review. Clinical coverage criteria added for follicular\nlymphoma and hairy cell leukemia. Updated B-cell lymphoma\nformatting. Updated background and reference.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}